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ABSTRACT
A wide range of genetic mouse models is available to help
researchers dissect human disease mechanisms. Each type of
model has its own distinctive characteristics arising from the nature of
the introduced mutation, as well as from the specific changes to the
gene of interest. Here, we review the current range of mouse models
with mutations in genes causative for the human neurodegenerative
disease amyotrophic lateral sclerosis. We focus on the two main
types of available mutants: transgenic mice and those that express
mutant genes at physiological levels from gene targeting or from
chemical mutagenesis. We compare the phenotypes for genes in
which the two classes of model exist, to illustrate what they can teach
us about different aspects of the disease, noting that informative
models may not necessarily mimic the full trajectory of the human
condition. Transgenic models can greatly overexpress mutant or wild-
type proteins, giving us insight into protein deposition mechanisms,
whereas models expressing mutant genes at physiological levels
may develop slowly progressing phenotypes but illustrate early-stage
disease processes. Although no mouse models fully recapitulate the
human condition, almost all help researchers to understand normal
and abnormal biological processes, providing that the individual
characteristics of each model type, and how these may affect the
interpretation of the data generated from each model, are considered
and appreciated.
KEY WORDS: Amyotrophic lateral sclerosis, ALS, Transgenic,
Knock-in, ENU, Gene targeted
Introduction
Amyotrophic lateral sclerosis (ALS) is a progressive
neurodegenerative disorder first described in 1869 by Jean-Martin
Charcot (Charcot and Joffroy, 1869). It has a mean incidence of ∼2/
100,000 worldwide and a prevalence of ∼6/100,000 in Europe
(Costa and de Carvalho, 2016; Marin et al., 2016), with a lifetime
risk of ∼1 in 300 in Western populations (Brown and Al-Chalabi,
2017). ALS patients typically present a focal onset, starting as
unilateral limb weakness or bulbar impairment. Clinical symptoms
usually start in mid-life and are a consequence of the dysfunction
and death of motor neurons (MNs) in the primary motor cortex,
brainstem and spinal cord, which causes spasticity, weakness and
muscle wasting, gradually leading to paralysis and death from
respiratory failure, typically less than 5 years from diagnosis
(Huynh et al., 2016; Van Damme et al., 2017).
There are no effective treatments for ALS apart from daily care
and support to counteract the symptoms. Currently, there are only
two US Food and Drug Administration (FDA)- and European
Medicines Agency (EMA)-approved neuroprotective drugs that
increase the lifespan of some patients by a few months: Riluzole,
which blocks excessive glutamatergic neurotransmission, and
Edaravone, which prevents oxidative stress damage.
Although 90% of ALS patients have sporadic (sALS) disease
without apparent family history, ∼5-10% of cases are familial
(fALS), usually showing monogenic autosomal dominant
inheritance (Brown and Al-Chalabi, 2017). In 1993, the first
causative gene for ALS was discovered, encoding the enzyme
Cu/Zn superoxide dismutase 1 (SOD1) (Rosen et al., 1993).
Research shows that SOD1-ALS accounts for ∼20% of fALS and
∼2% of sALS, with >150 mutations identified throughout the
coding region and causing an unknown toxic gain of function
(GOF) (Saccon et al., 2013; Kaur et al., 2016). SOD1 is
ubiquitously expressed and important for the removal of free
radicals, although it likely has other non-canonical roles; for
example, as a transcriptional regulator under oxidative stress,
possibly as an RNA-binding protein and a signalling molecule
(Bunton-Stasyshyn et al., 2015).
Since the discovery of SOD1’s association with ALS, mutations
in more than 20 genes were found to be causative, most with
an autosomal-dominant pattern of transmission, together with >30
potential disease-modifying genes (Li and Wu, 2016). Causative
genes include the chromosome 9 open reading frame 72 (C9ORF72),
in which an intronic hexanucleotide repeat expansion gives rise to
ALS. This mutation is the most common cause of fALS, and is found
in up to 40% of fALS and ∼9% of sALS in Caucasians (DeJesus-
Hernandez et al., 2011; Renton et al., 2011; Goldstein et al., 2018).
Other well known ‘ALS genes’ include TAR DNA-binding protein
(TARDBP; encoding TDP-43), found in ∼5% of fALS and ∼2% of
sALS, and fused in sarcoma (also known as FUS RNA-binding
protein; FUS), found in∼6% of fALS and∼1% of sALS (Ingre et al.,
2015; Tarlarini et al., 2015). TDP-43 and FUS are RNA-binding
heterogeneous nuclear ribonucleoproteins (hnRNPs) mainly
localised in the nucleus, and are involved in mRNA splicing, gene
transcription and microRNA maturation, mRNA shuttling from the
nucleus to the cytoplasm and stress granule formation. Cytoplasmic
mislocalisation and nuclear depletion of TDP-43 is a key feature of
most ALS cases and may contribute to disease pathogenesis
(Guerrero et al., 2016). Protein aggregates containing truncated
hyperphosphorylated and/or ubiquitinated TDP-43 are found within
MNs in >95% of ALS-affected brains and spinal cords (Chou et al.,
2018), and can occur in other neurological disorders, including
Alzheimer’s, Parkinson’s and Huntington’s diseases, highlighting
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the importance of TDP-43 in neurodegeneration (Liu et al., 2017;
St-Amour et al., 2018).
Other genes less frequently mutated in ALS include coiled-
coil-helix-coiled-coil-helix domain-containing 10 (CHCHD10)
(Bannwarth et al., 2014), kinesin family member 5A (KIF5A)
(Brenner et al., 2018), matrin 3 (MATR3) (Johnson et al., 2014),
optineurin (OPTN) (Maruyama et al., 2010), profilin 1 (PFN1) (Wu
et al., 2012), senataxin (SETX) (Chen et al., 2004), sequestosome 1
(SQSTM1/p62) (Fecto, 2011), TANK-binding kinase 1 (TBK1)
(Cirulli et al., 2015; Freischmidt et al., 2015), ubiquilin 2
(UBQLN2) (Deng et al., 2011), valosin-containing protein (VCP)
(Johnson et al., 2010) and VAMP-associated protein B and C
(VAPB) (Nishimura et al., 2004). As each new gene is identified, the
next step is to make a mouse model. There are different types of
mutant mice, which yield different insights and should be used to
address different research questions.
Mouse models of ALS
We know little of early-stage ALS pathomechanisms, and we still
have a lot to learn about the disease trajectories for fALS and sALS.
Here, we discuss the main features of the different types of mouse
models that are helping us to elucidate the molecular pathology of
ALS and its phenotypic implications: transgenic mice, and targeted
and ENU mutant mice (Fig. 1). We then focus on comparing the
phenotypes of mice with ALS gene mutations for which at least two
of these types of model have been published; namely, FUS, SOD1,
TARDBP, VAPB, VCP and UBQLN2.
Transgenic mouse models
ALS is mostly an autosomal-dominant disorder and therefore the
majority of mouse models have been transgenic lines, made by
randomly inserting human (in most cases) mutant ALS genes into
the mouse genome (Table 1). This is a fast method of producing new
strains and, because the disease is dominant, the phenotype usually
manifests, despite the presence of intact orthologous mouse genes.
Indeed, the first model of ALS, the SOD1G93A transgenic strain
[Tg(SOD1*G93A)1Gur], was published a year after the discovery
of SOD1-ALS mutations in humans (Gurney et al., 1994)
(Table 1A) and remains the most commonly used ALS mouse
model. Owing to the early onset, fast disease progression towards an
early humane endpoint, progressive MN loss and low variability of
the phenotype on defined genetic backgrounds, the SOD1G93A
transgenic strain has become the workhorse for testing therapeutics
aimed at ameliorating ALS.
Around 30 FUS and TARDBP mutant transgenic lines have also




Gene-targeted Vcp R155H 
(Yin et al., 2012)
Early stage




with diffuse muscle weakness
Last stage
Final-stage paralysis 
with ≥50% MN loss 
Gene-targeted partially humanised
FUSDelta14 
(Devoy et al., 2017)
ENU Sod1 D83G
(Joyce et al., 2014)
ENU Tardbp M323K 
(Fratta et al., 2018)
Transgenic SOD1 G93A
(Gurney et al., 1994)
Transgenic VAPB P56S
(Aliaga et al., 2013)
Transgenic FUS R521C
(Qiu et al., 2014)
Transgenic TARDBP Q331K
(Mitchell et al., 2015)
Transgenic UBQLN2 P497S
(Le et al., 2016)
Gene-targeted Fus ΔNLS
(Scekic-Zahirovic et al., 2016, 2017)
Fig. 1. Features of transgenic versus physiological mouse models for studying ALS. Examples from Table 1, showing potential windows of ALS pathology
to investigate using transgenic or physiological mouse models; lengths of arrows correspond, approximately, to the severity of the phenotype on either
heterozygous or homozygous mice at the oldest age measured, as per the references. We note that with respect to ALS genetic models, the SOD1 G93A
(Gurney et al., 1994) mouse was the first transgenic line. We believe that Vcp R155H (Badadani et al., 2010; Yin et al., 2012) was the first gene-targeted model,
the Sod1 D83G (Joyce et al., 2015) line was the first ENU mouse model, and the FUSDelta14 model (Devoy et al., 2017) was the first genomically humanised
knock-in to the endogenous mouse locus, although this is a partial humanisation; see Table 1.
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In contrast, only one of the published UBQLN2 transgenic lines,
carrying the P497S mutation, which disturbs proteasomal
degradation, shows motor impairment, mild MN loss (20%) and
cytoplasmic aggregates positive for ubiquitin and TDP-43 (Le et al.,
2016) (Table 1D). The only mouse model expressing a mutated
VAPB protein has a progressive phenotype resulting in ∼60% MN
loss by 78 weeks of age (Aliaga et al., 2013) (Table 1E), whereas
results are mixed for the VCP transgenic models (Table 1F). Despite
the variability in phenotype presentation, transgenic mice remain a
critical resource for understanding neurodegeneration but, like all
mouse models, they have generic characteristics we need to take into
account, as discussed below.
Site of insertion
Transgene DNA is usually microinjected into fertilised eggs and
randomly inserts into the host mouse genome. This can lead to
insertional mutagenesis from disrupting a host gene, producing an
aberrant phenotype, which is why multiple founder lines from
independent transgenic embryos are studied – to be confident that
the common phenotypes arise from the transgene. Almost all
transgenic lines in Table 1 do not have information on the insertion
site, as is the case for the vast majority of transgenic models of
neurodegenerative disease (Tosh et al., 2017; Goodwin et al., 2017).
Fortunately, in SOD1G93Amice, the transgene insertion site does not
disrupt a known gene (Srivastava et al., 2014; Achilli et al., 2005).
Transgene copy number and gene expression
Transgenic DNA tends to concatemerise as it inserts into the genome,
leading to multiple copies of the exogenous sequence. This results in
the overexpression of the protein of interest, often leading to
accelerated phenotypes. Furthermore, a caveat to studying transgenic
mice arises from the development of aberrant phenotypes due to
overexpression. The SOD1G93A model used most commonly carries
∼25 copies of the human transgene, resulting in overexpression of the
protein (Gurney et al., 1994; Shibata, 2001), with MN degeneration
progressing rapidly: disease onset occurs at∼90 days and the humane
endpoint occurs by ∼130 days of age, depending on the genetic
background of themouse. However, transgenic mice expressingwild-
type human SOD1 at a similar level to mice expressing the mutant
transgene have neurological phenotypes likely arising from
overexpression and not from mutation, including spinal cord
vacuolation with early signs of paresis in one or more limbs
(Jaarsma et al., 2000) and evenMN loss (Graffmo et al., 2013). Thus,
the ideal controls for mutant transgenic mice are transgenic animals
expressing thewild-type transgene at similar levels to themutantmice
to control for the effects of overexpression per se. However, the wild-
type human SOD1 transgenic lines are not without problems. For
example, transgene insertion sites have not been assessed, and
although they develop phenotypes relevant to MN disease, these are
more profound in some of the mutant SOD1 transgenic lines, such as
the SOD1G93A model. Nevertheless, a large proportion of ALS
studies in mutant transgenic mice do not use wild-type transgenic
controls, and this is an option that should at least be considered for
future work.
Some genes are highly dosage sensitive and a subtle deviation
from the physiological levels leads to aberrant phenotypes, even
when the protein product is wild type. Many of the RNA-binding
proteins that cause ALS when mutated belong to this category,
including TDP-43 and FUS (Table 1B,C). For example, transgenic
mice overexpressing wild-type human TARDBP (from a Thy1.2
promoter) by 1.2× to 2× fold over the endogenous gene level have
25% MN loss with rare cytoplasmic inclusions containing TDP-43
(Wils et al., 2010). Overexpression of human wild-type FUS (under
the mouse prion promoter) results in aggregation of human FUS
protein and 60% loss of MNs in homozygous transgenic mice,
leading to a more severe phenotype in homozygotes than in
hemizygotes (Mitchell et al., 2013) (Table 1C). Indeed, RNA-
binding proteins such as TDP-43 often control the expression levels
of their own transcript through autoregulation. Therefore, when
transgene expression levels of wild-type or mutant proteins rise
above a threshold, the expression levels of the mouse endogenous
transcripts are reduced, possibly contributing towards toxicity.
Furthermore, transgenes are often engineered to have exogenous
promotors to ensure high levels of expression in the tissues of interest,
but such ectopic expression can result in novel phenotypes. For
example, two unrelated transgenic mouse lines overexpressing VCP
with the R155H mutation, under the control of a muscle creatine
kinase (mMCK) or a cytomegalovirus (CMV) promotor, have
differences in the survival and presence of cytoplasmic aggregates
containing VCP, and variability in the levels of motor impairment
(Table 1F) (Weihl et al., 2007; Custer et al., 2010). Similarly,
transgenic mice overexpressing mutant human TARDBPA315T driven
by the mouse prion promoter (the activity of which is strong in
neurons, although it is also widely expressed in other cell types)
unexpectedly die early from neurodegeneration in the gut rather than
in MNs (Wegorzewska et al., 2009; Hatzipetros et al., 2014).
Finally, the transgene arraymay alter copy number at meiosis; thus,
colonies need to be monitored constantly because the transgene’s
copy number usually determines phenotype severity. For example,
the Tg(SOD1*G93Adl)1Gur (SOD1G93Adl; also known as G1del)
mice appear to have arisen from a deletion in the transgene array of a
SOD1G93A mouse (http://jaxmice.jax.org/strain/002300.html). The
resulting ‘low copy’ SOD1G93A transgenic mouse strain carries∼8-10
copies of the human SOD1G93A transgene instead of the ∼25 in the
progenitor line, and these ‘low copy’ animals develop paralysis
between 24 and 34 weeks of age, considerably later than the ‘high
copy’ progenitor line (Alexander et al., 2004; Acevedo-Arozena
et al., 2011).
BAC transgenic mice
Most – but not all transgenic animals – have been made with the
longest known complementary DNA (cDNA) sequence for the gene
of interest; this is usually because of constraints on DNA insert size
in the plasmid vectors used to subclone the transgenic constructs. To
avoid this size limit and to generate mice carrying the full genomic
architecture of a gene (which is particularly important in the case of
C9ORF72-ALS, for which the mutation is intronic), researchers can
generate transgenic mice with bacterial artificial chromosome
(BAC) vectors, which can carry inserts of up to ∼200 kb. This
approach was used to generate, for example, C9ORF72 (Balendra
and Isaacs, 2018), TDP-43 (Swarup et al., 2011) and FUS (López-
Erauskin et al., 2018) BAC transgenic mice. BACs randomly insert
into the mouse genome, but generally with very low copy numbers
(one to three copies), limiting the effects of overexpression of the
gene of interest, although even subtle overexpression can alter the
phenotype. As with all transgenics, there is the undesired possibility
of insertion mutagenesis, in which integration of the transgene can
disrupt an important gene.
Generic transgenic mouse features for ALS research
Until recently, transgenics were the fastest technology to obtain
genetically modified mice, but this is changing as CRISPR/Cas9-
based technologies develop. As discussed above, phenotypes can be
rapid and severe in transgenic models because of expression of the
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transgene above endogenous levels. This is helpful for understanding
the advanced stages of disease, which in the natural history of ALS is
comparable to when most patients receive the diagnosis. Several
transgenic models can have quantifiable, progressive loss of MNs
severe enough to lead to profound locomotion defects and paralysis
during the mouse lifespan (Table 1). These features made them the
models of choice for pre-clinical studies and, until recently, almost all
ALS therapeutics were solely tested on SOD1 transgenic models.
This provides some explanation for the past failures of translating
promising therapeutics from SOD1 transgenics to ALS patients, 98%
of whom do not suffer from SOD1-ALS (Urushitani et al., 2007;
Turner and Talbot, 2008; Riboldi et al., 2011; Vallarola et al., 2018).
Mouse models with mutations at physiological levels in
endogenous genes
Gene-targeted and ENU mutant strains
Mouse models of ALS can be generated by mutating mouse gene
orthologues, to express the relevant protein at physiological levels.
Here, we discuss the two key types of model with mutations in
endogenous genes, produced from gene-targeting strategies or by
random mutagenesis with the chemical N-ethyl-N-nitrosourea
(ENU). We describe both as ‘physiological’ models in this article,
as ‘knock-in’ (KI) is generally used for gene-targeted mice because
it implies purposely engineering the mouse genome.
Gene-targeted models of ALS
Gene targeting entails introducing specific changes to a DNA
sequence of interest. In mice, perhaps its most common use has been
to create knockout (KO) animals in which the gene no longer
functions, usually to help us understand the biology of individual
genes. For example, the International Mouse Knockout program
aims to functionally KO each mouse gene, providing phenotypic
data for each KO line under the International Mouse Phenotyping
program (Muñoz-Fuentes et al., 2018).
Gene KOs
Although most forms of ALS appear to be caused by toxic dominant
GOF, KO models are an important resource as they can reveal not
only critical gene function but also whether there is a loss-of-
function (LOF) component to disease pathogenesis. For example,
TDP-43 is usually depleted from the nucleus of MNs in TDP-43-
ALS, presumably leading to a loss of nuclear TDP-43 function.
Although homozygous TDP-43 KO mice are not viable, and
heterozygous KO mice express a normal amount of TDP-43 protein
due to its autoregulation, conditional TDP-43 KO lines and a
transgenic line expressing small interfering RNA against TDP-43
develop MN degeneration (Kraemer et al., 2010), showing that
acute TDP-43 LOF can be a driver of neurodegeneration. In SOD1-
ALS, LOF can play a role in disease pathogenesis, as Sod1KOmice
develop a severe peripheral neuropathy, leading to denervation
(Fischer et al., 2011) and SOD1-ALS patients generally have
diminished SOD1 dismutase activity (Saccon et al., 2013).
KI mutations
Gene targeting has been used to insert specific mutations, usually
(but not always; see Sharma et al., 2016; Gordon et al., 2019) into
the endogenous mouse gene, with the aim of maintaining
physiological expression levels of the (mutant) protein. This
approach has been used thus far for Fus, Tardbp, Vapb, Vcp and
Ubqln2 mutations.
Classical gene targeting involves creating recombinant vectors
for homologous recombination in mouse embryonic stem cells,
which can be time-consuming and relatively expensive. However,
CRISPR/Cas9 targeting in zygotes has made the production of
gene-targeted mice – for example, such as two recently described
strains recapitulating the human TARDBP Q331K mutation (Fratta
et al., 2018; White et al., 2018) – considerably more efficient, faster
and cheaper. Nevertheless, the possible off-target effects of this
technology must be taken into account (Zhang et al., 2015).
One of the first KIs to model ALS was the VcpR155H strain
(Badadani et al., 2010; Yin et al., 2012). These mice have age-
dependent degeneration of ventral horn MNs with up to 50% MN
loss, TDP-43-positive cytoplasmic inclusions, mitochondrial
aggregation and progressive astrogliosis. These and other Vcp KI
mice do not have rapidly progressive fatal ALS features, but they are
important for understanding the onset of ALS (Table 1F).
Site-directed insertion of exogenous DNA into known ‘safe
harbour’ sites in the genome, such as the Rosa26 locus, also uses
homologous recombination and is an alternative that avoids the
random insertion mutagenesis of transgenic approaches. For
example, TDP-43 KI mice have been generated by inserting the
complete human TARDBP gene from a BAC, including introns and
regulatory elements, into the Rosa26 locus. These mice show low
levels of human TDP-43 expression compared with their
endogenous TDP-43, absence of inclusions or gliosis, and a mild
age-dependent motor dysfunction, which may give insight into
early-stage disease (Gordon et al., 2019).
Genomic humanisation
Gene targeting, by homologous recombination or CRISPR/Cas9,
enables us to make complex changes in mouse genes, including
knocking in human genomic loci that carry important sequences for
understanding disease and using these to completely replace the
endogenous mouse genes. The FUSDelta14 KI heterozygous mice,
expressing a partially humanised mutant FUS gene, carrying a
splice acceptor site mutation that results in a frameshift that causes
an aggressive form of ALS in humans, show progressive spinal MN
loss, cytoplasmic mislocalisation of FUS and impaired lipid
metabolism (Devoy et al., 2017) (Table 1C). An interesting
avenue yet to be explored is the full humanisation of ALS genes.
The biochemistry of human proteins, such as SOD1, is sometimes
different from that of mouse orthologues, which could be relevant
for disease modelling (Prudencio et al., 2009; Karch and Borchelt,
2010; Seetharaman et al., 2010). However, full humanisation of a
gene in the context of the mouse genome remains technically
challenging and may lead to artefactual results arising from altering
the mouse cellular pathways. Thus, each model will have to be
assessed carefully on a case-by-case basis and with wild-type
human gene controls.
Generic gene-targeted mutant mouse features for ALS research
Gene-targeted models express the gene of interest at physiological
levels and more closely recapitulate the human ALS-causing
mutations at both the genetic and biochemical levels. Together with
transgenic models, they can also advance our understanding of
disease pathomechanisms, as the technology allows the development
of inducible or conditional models that dissect the timing and cell
specificity of disease processes. For example, FUSΔNLS mice
express a truncated FUS protein lacking the nuclear localisation
signal (NLS), with floxed exons 13 and 14 followed by stop codons
and a polyadenylation signal, allowing Cre-mediated reversal of the
MN loss phenotype, giving new insight into the potential effects of
ALS therapies at different disease stages (Scekic-Zahirovic et al.,
2016) (Table 1C). However, although few ALS KI models have been
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produced so far, as is clear from Table 1, the phenotypes of KI mice
are oftenmild and progress slowly. For example, KImodels ofmutant
Vapb and Ubqln2 do not show strong, overt ALS features (Table 1D,
F). Nevertheless, they are likely essential for understanding disease
onset and the very earliest pathogenic mechanisms, and for
developing important biomarkers.
Random chemical mutagenesis
Random mutagenesis of the mouse genome can give unexpected
insight into human biology. Although other methods exist, such as
the use of viral integration or radiation treatment, the majority of
such mutant mouse models described in the literature come from the
use of the powerful chemical mutagen ENU (Acevedo-Arozena
et al., 2008). Typically, male mice are injected with ENU, left for
several weeks until they start to produce mutant sperm and then
mated to wild-type females. Their progeny, carrying point
mutations, are assessed for phenotype in a forward genetics
screen using wide-ranging tests, so that researchers interested in,
for example, progressive locomotor mutants, may determine the
causative point mutation and explore the underlying mechanism
(Potter et al., 2016). This experimental design is also known as a
‘phenotype screen’. In parallel, sperm and DNA from male progeny
are banked for ‘genotype screens’, in which researchers assay the
DNA (usually tens of thousands of samples from a single large ENU
program) for point mutations in their gene of interest. The
corresponding stored sperm samples are then used for in vitro
fertilisation to (re)derive the relevant mouse line (Stottmann and
Beier, 2014).
An informative example of an ENUmutant for ALS research was
identified in a genotype screen of Sod1 within a DNA bank at the
mouse facility atMRCHarwell in the UK (Table 1A). This strain, on
a C57BL/6J background, carries a Sod1D83G mutation that is
orthologous to the human SOD1D83G fALSmutation. Heterozygous
animals only start to show mild locomotor effects at ∼88 weeks of
age, but homozygous mutant mice have a striking phenotype that
has allowed the separation of Sod1 LOF acting in the periphery and
GOF effects in MN soma arising from mutant mouse Sod1 (Joyce
et al., 2015).
Generic ENU mutant mouse features for ALS research
Depending on the dose of ENU, the progeny will have multiple
mutations within their genome, not just in the gene of interest. Thus,
these animals must be backcrossed for several generations to
segregate away other mutations, and the flanking congenic region
must be carefully assessed to avoid any confounding effects of
nearby point mutations (Keays et al., 2007).
One of the advantages of working with ENU mice is the
possibility of unexpected insights from novel mutations. However, a
disadvantage is that a mutation identified in a genotype screen may
not guarantee an aberrant phenotype. For example, our own group
identified mouse samples with ENU-induced point mutations in
Tardbp, but extensive assessment of a rederived strain with a
truncated TDP-43 (carrying a TardbpQ101X mutation) revealed only
limited phenotypes (Ricketts et al., 2014). Nevertheless, as our
knowledge of the biochemistry and structure of ALS proteins
improves, we can parse ENU mutants by protein domain to help
decide which mice to rederive for study. Thus, in follow-up work,
our group went on to investigate two more Tardbp mutants, one
carrying a mutation (M323K) within the low complexity domain
(LCD), and the other with a mutation (F210I) in the second RNA-
binding domain (RRM2) of TDP-43. The LCDmutation results in a
progressive loss of spinal MNs, whereas the RRM2 mutation
behaves as a LOF. Importantly for ALS research, transcriptomic
analysis of these mice showed that C-terminal TDP-43 mutations
lead to a TDP-43 gain-of-splicing function when mutations are
expressed at physiological levels. This mutant TDP-43 GOF affects
the splicing of a subset of genes not previously known to be
controlled by TDP-43, leading to the appearance of new exon
exclusion events called ‘skiptic exons’ that are, at least partially, also
present in human TDP-43-ALS fibroblast cells (Fratta et al., 2018)
(Table 1b).
The TDP-43 ENU mutants highlight another property of ENU
mutagenesis: using this method it is relatively straightforward to
generate allelic series of animals that may help us dissect protein
function.
Transgenic compared with gene-targeted and ENU mouse
models for ALS research
Mice and humans are different animals, and we should not expect a
single mouse model to fully recapitulate the entire trajectory of
human neurodegenerative disease. We have summarised the key
features of two generic types of mouse model – transgenic animals
and those that express the gene/mutation of interest at physiological
levels – looking at the ease of making each model, and at the types
of phenotypes they develop, which usually vary largely because of
different expression levels of the gene of interest.
For ALS alleles with dominant modes of inheritance, or where
researchers wish to alter protein structure to help dissect function,
we have a choice of the type of model to study, and each generic
model has different applications (Table 1). Physiological models
(gene-targeted and ENU models) have slower progression of
phenotypes, which are less severe than in transgenic mice,
presumably because proteins are not being overexpressed.
However, they maintain correct spatial and temporal levels of
expression, which is crucial to avoid the dose-dependent toxicity of
some proteins, allowing the study of interactions between the gene/
protein of interest and its partners within a pathway over the
animal’s life span. Moreover, the late disease onset in these mice is
useful for gaining insight into the pre-symptomatic stages, and to
identify early biomarkers. However, slow phenotypes make these
animals expensive to study, as statistically significant differences
from their wild-type littermates may only arise after a year or more
of life, incurring significant husbandry costs. Nevertheless, they
provide a wide window onto early-stage disease processes. In
contrast, transgenic animals tend to express strong phenotypes and
clear MN loss, making them potentially more relevant to end-stage
processes. These differences are exemplified by Vapb and Ubqln2
KI models that have been valuable to study potentially impaired
autophagy and proteasomal degradation mechanisms in ALS
pathogenesis, but which do not develop the motor impairment or
MN loss that can arise in their transgenic counterparts (Table 1D,E).
Mice carrying the TDP-43 Q331K fALS mutation (Table 1B)
offer another comparison between gene-targeted KI and transgenic
strains. TardbpQ331K KIs model the toxic TDP-43 GOF, providing
insight into the splicing alteration and the protein autoregulation
impairment while reproducing aspects of frontotemporal dementia,
although they do not show TDP-43 inclusions or MN loss (White
et al., 2018; Fratta et al., 2018). In contrast, the TDP-43 Q331K
transgenic line, with transgene expression driven by the mouse
prion promotor, shows MN loss, muscle degeneration and
neuromuscular junction loss with motor impairments, but only
when the transgene is overexpressed above a threshold, confirming
the dose-dependent toxic effects of TDP-43 expression (Arnold
et al., 2013). Other conditional transgenic lines, such as
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hTDP-43ΔNLSmice devoid of the TDP-43 NLS, model the toxicity
caused by cytoplasmic accumulation and nuclear depletion of TDP-
43 (Igaz et al., 2011) (Table 1B).
In summary, several different types of mouse model have been
developed worldwide with the aim of reproducing ALS-like
phenotypes for functional dissection (Table 1), and it is clear that
having access to both transgenic and endogenous mice for each ALS
gene could help build a comprehensive picture of the effects of
different human ALS mutations.
Making use of all available ALS-related mouse strains
ALS is probably not a single disease, but arises sporadically and
from mutations in a number of genes with varied functions. Mouse
models can help us to unravel this complex picture by comparing
phenotypes across ALS gene models (Fig. 1). For example, rNLS8
mice, a transgenic model expressing cytoplasmic TDP-43, showed
that reactive microglia have an important role in rescuing MN
degeneration caused by cytoplasmic TDP-43 expression (Spiller
et al., 2018). This is in contrast to SOD1G93A transgenics, in which
transplant of wild-type microglia significantly delays MN
degeneration (Wu et al., 2006; Beers et al., 2006). These
contrasting results highlight that there are specific disease
trajectories in different mouse models, which is also likely the
case in ALS patients. Therefore, moving forward, it will be critical
to use a variety of models (mouse and other) to understand ALS
pathogenesis more broadly, and there remains a need for more
models for different ALS genes.
What is a good mouse model?
This brings us to a key question: what is a good mouse model? The
short answer is the animal that is most informative for the
underlying biology/disease under study. However, a more
considered answer is that researchers must first define the features
they are interested in, then chose the most appropriate model. Or
better, choose different models to study the disease as broadly as
possible. For example, are we looking for subtle, early molecular
changes in spinal MNs, or are we interested in models with upper
and lower MN death, or are we focusing on the role of glia?
There are many other factors to obtaining a useful mouse model
and here we have discussed just one aspect – albeit the crucial one –
of model design, i.e. how was the model generated. However, a
mouse model’s phenotype also depends on the same factors as in
humans, including sex and genetic background, which can have
profound effects on how a mutation manifests. This is why we have
been careful to include these descriptors in Table 1 (Bruijn et al.,
2004; Heiman-Patterson et al., 2011; Mancuso et al., 2012; Nardo
et al., 2013). Similarly, the environment can markedly affect disease
manifestation; for example, environmental enrichment (such as
running wheels and nesting material) can increase the life span and
behavioural performance in SOD1-G93A mice (Sorrells et al.,
2009). Conversely, single housing is a cause of stress in mice and
can lead to decreased life span (Kalliokoski et al., 2014), whereas
good physical and social interactions positively affect animal
welfare (Sundberg and Schofield, 2018).
Mouse models remain necessary for studying ALS, which is a
collection of diseases that are not – as far as we know – cell
autonomous and that involve different systems, including the
immune system. Animal models provide a complex in vivo
environment of tissues and cell–cell interactions, which are
fundamental for the study of complex neurodegenerative diseases,
such as ALS, in which the interactions between glia, MNs and
muscle are likely necessary for disease development.
The final word
In gathering the information for this Review to populate the
comprehensive Table 1, we found many inconsistencies in the
literature describing new mouse lines. It is crucial that descriptions
are as complete as possible to define the specific pathology of a
model, including reporting the absence of important features, such
as MN degeneration, and other negative results. The use of Animal
Research: Reporting of In Vivo Experiments (ARRIVE) guidelines
(Kilkenny et al., 2014) will improve reporting of mouse model
phenotypes. In addition, it is critical to make new models freely
available via The European Mouse Mutant Archive (EMMA) or
The Jackson Laboratory (JAX).
The complexities of ALS are clearly exemplified by the wide
array of phenotypes arising in the plethora of mouse models
available. If anything, the past decades of research into ALS have
shown us that to improve our understanding of disease
pathogenesis, the community must embrace its complexities and
work with different models. In the near future, integrating data from
multiple sources, mouse and human, in vivo and in vitro, should
allow us to build a more complete picture of health and disease
states, over a lifetime. However, ultimately, we must relate our
findings back to humans, and cell, organoid and clinical models
remain essential for cross-referencing and validating the findings
from mouse studies.
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Marroquin, N., Nordin, F., Hübers, A., Weydt, P. et al. (2015).
Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia.
Nat. Neurosci. 18, 631-636.
Goldstein, O., Gana-Weisz, M., Nefussy, B., Vainer, B., Nayshool, O., Bar-Shira,
A., Traynor, B. J., Drory, V. E. and Orr-Urtreger, A. (2018). High frequency of
C9orf72 hexanucleotide repeat expansion in amyotrophic lateral sclerosis
patients from two founder populations sharing the same risk haplotype.
Neurobiol. Aging 64, 160.e1-160.e7.
Goodwin, L. O., Splinter, E., Davis, T. L., Urban, R., He, H., Braun, R. E., Chesler,
E. J., Kumar, V., Van Min, M., Ndukum, J. et al. (2017). Large-scale discovery of
mouse transgenic integration sites reveals frequent structural variation and
insertional mutagenesis. bioRxiv, 1-27.
Gordon, D., Dafinca, R., Scaber, J., Alegre-Abarrategui, J., Farrimond, L.,
Scott, C., Biggs, D., Kent, L., Oliver, P. L., Davies, B. et al. (2019). Single-copy
expression of an amyotrophic lateral sclerosis-linked TDP-43mutation (M337V) in
BAC transgenic mice leads to altered stress granule dynamics and progressive
motor dysfunction. Neurobiol. Dis. 121, 148-162.
Gorrie, G. H., Fecto, F., Radzicki, D., Weiss, C., Shi, Y., Dong, H., Zhai, H., Fu, R.,
Liu, E., Li, S. et al. (2014). Dendritic spinopathy in transgenic mice expressing
ALS/dementia-linked mutant UBQLN2. Proc. Natl Acad. Sci. USA 111,
14524-14529.
Graffmo, K. S., Forsberg, K., Bergh, J., Birve, A., Zetterstrom, P., Andersen,
P. M., Marklund, S. L. and Brannstrom, T. (2013). Expression of wild-type
human superoxide dismutase-1 in mice causes amyotrophic lateral sclerosis.
Hum. Mol. Genet. 22, 51-60.
Guerrero, E. N., Wang, H., Mitra, J., Hegde, P. M., Stowell, S. E., Liachko, N. F.,
Kraemer, B. C., Garruto, R. M., Rao, K. S. and Hegde, M. L. (2016). TDP-43/
FUS in motor neuron disease: complexity and challenges. Prog. Neurobiol. 145-
146, 78-97.
Gurney, M., Pu, H., Chiu, A., Dal Canto, M., Polchow, C., Alexander, D.,
Caliendo, J., Hentati, A., Kwon, Y., Deng, H. et al. (1994). Motor neuron
degeneration in mice that express a human Cu,Zn superoxide dismutase
mutation. Science 264, 1772-1775.
Han-Xiang, D., Hujun, J., Ronggen, F., Hong, Z., Yong, S., Erdong, L., Makito,
H., Mauro, C. D. C. and Teepu, S. (2008). Molecular dissection of ALS-
associated toxicity of SOD1 in transgenic mice using an exon-fusion approach.
Hum. Mol. Genet. 17, 2310-2319.
Hatzipetros, T., Bogdanik, L. P., Tassinari, V. R., Kidd, J. D., Moreno, A. J.,
Davis, C., Osborne, M., Austin, A., Vieira, F. G., Lutz, C. et al. (2014). C57BL/6J
congenic Prp-TDP43A315T mice develop progressive neurodegeneration in the
myenteric plexus of the colon without exhibiting key features of ALS. Brain Res.
1584, 59-72.
Heiman-Patterson, T. D., Sher, R. B., Blankenhorn, E. A., Alexander, G., Deitch,
J. S., Kunst, C. B., Maragakis, N. and Cox, G. (2011). Effect of genetic
background on phenotype variability in transgenic mouse models of amyotrophic
lateral sclerosis: a window of opportunity in the search for genetic modifiers.
Amyotroph Lateral Scler. 12, 79-86.
Hjerpe, R., Bett, J. S., Keuss, M. J., Solovyova, A., Mcwilliams, T. G., Johnson,
C., Sahu, I., Varghese, J., Wood, N., Wightman, M. et al. (2016). UBQLN2
mediates autophagy-independent protein aggregate clearance by the
proteasome. Cell 166, 935-949.
Huynh, W., Simon, N. G., Grosskreutz, J., Turner, M. R., Vucic, S. and Kiernan,
M. C. (2016). Assessment of the upper motor neuron in amyotrophic lateral
sclerosis. Clin. Neurophysiol. 127, 2643-2660.
Igaz, L. M., Kwong, L. K., Lee, E. B., Chen-Plotkin, A., Swanson, E., Unger, T.,
Malunda, J., Xu, Y., Winton, M. J., Trojanowski, J. Q. et al. (2011).
Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and
degeneration in mice. J. Clin. Investig. 121, 726-738.
Ingre, C., Roos, P. M., Piehl, F., Kamel, F. and Fang, F. (2015). Risk factors for
amyotrophic lateral sclerosis. Clin. Epidemiol. 7, 181-193.
Jaarsma, D., Haasdijk, E. D., Grashorn, J. A. C., Hawkins, R., Van Duijn, W.,
Verspaget, H. W., London, J. and Holstege, J. C. (2000). Human Cu/Zn
Superoxide Dismutase (SOD1) overexpression in mice causes mitochondrial
vacuolization, axonal degeneration, and premature motoneuron death and
accelerates motoneuron disease in mice expressing a familial amyotrophic
lateral sclerosis mutant SOD1. Neurobiol. Dis. 7, 623-643.
Jaarsma, D., Teuling, E., Haasdijk, E. D., De Zeeuw, C. I. and Hoogenraad, C. C.
(2008). Neuron-specific expression of mutant superoxide dismutase is sufficient
to induce amyotrophic lateral sclerosis in transgenic mice. J. Neurosci. 28,
2075-2088.
Janssens, J., Wils, H., Kleinberger, G., Joris, G., Cuijt, I., Ceuterick-De Groote,
C., Van Broeckhoven, C. and Kumar-Singh, S. (2013). Overexpression of ALS-
associated p.M337V human TDP-43 in mice worsens disease features compared
to wild-type human TDP-43 mice. Mol. Neurobiol. 48, 22-35.
Johnson, J. O., Mandrioli, J., Benatar, M., Abramzon, Y., Van Deerlin, V. M.,
Trojanowski, J. Q., Gibbs, J. R., Brunetti, M., Gronka, S., Wuu, J. et al. (2010).
Exome sequencing reveals VCPmutations as a cause of familial ALS.Neuron 68,
857-864.
14


















Johnson, J. O., Pioro, E. P., Boehringer, A., Chia, R., Feit, H., Renton, A. E.,
Pliner, H. A., Abramzon, Y., Marangi, G., Winborn, B. J. et al. (2014). Mutations
in the Matrin 3 gene cause familial amyotrophic lateral sclerosis. Nat. Neurosci.
17, 664-666.
Jonsson, P. A., Ernhill, K., Andersen, P. M., Bergemalm, D., Brännström, T.,
Gredal, O., Nilsson, P. and Marklund, S. L. (2004). Minute quantities of
misfolded mutant superoxide dismutase-1 cause amyotrophic lateral sclerosis.
Brain 127, 73-88.
Jonsson, P. A., Graffmo, K. S., Andersen, P. M., Brännström, T., Lindberg, M.,
Oliveberg, M. and Marklund, S. L. (2006). Disulphide-reduced superoxide
dismutase-1 in CNS of transgenic amyotrophic lateral sclerosis models. Brain
129, 451-464.
Joyce, P. I., Mcgoldrick, P., Saccon, R. A., Weber,W., Fratta, P., West, S. J., Zhu,
N., Carter, S., Phatak, V., Stewart, M. et al. (2015). A novel SOD1-ALS mutation
separates central and peripheral effects of mutant SOD1 toxicity. Hum. Mol.
Genet. 24, 1883-1897.
Kalliokoski, O., Teilmann, A. C., Jacobsen, K. R., Abelson, K. S. P. and Hau, J.
(2014). The lonely mouse – single housing affects serotonergic signaling integrity
measured by 8-OH-DPAT-induced hypothermia in male mice. PLoS ONE 9,
e111065.
Karch, C. M. and Borchelt, D. R. (2010). Aggregation modulating elements in
mutant human superoxide dismutase 1. Arch. Biochem. Biophys. 503, 175-182.
Kaur, S. J., Mckeown, S. R. and Rashid, S. (2016). Mutant SOD1 mediated
pathogenesis of Amyotrophic Lateral Sclerosis. Gene 577, 109-118.
Keays, D. A., Clark, T. G., Campbell, T. G., Broxholme, J. and Valdar, W. (2007).
Estimating the number of coding mutations in genotypic and phenotypic driven N-
ethyl-N-nitrosourea (ENU) screens: revisited. Mamm. Genome 18, 123-124.
Kilkenny, C., Browne, W., Cuthill, I., Emerson, M. and Altman, D. (2014).
Improving bioscience research reporting: the ARRIVE guidelines for reporting
animal research. Animals 4, 35-44.
Kraemer, B. C., Schuck, T., Wheeler, J. M., Robinson, L. C., Trojanowski, J. Q.,
Lee, V. M. Y. and Schellenberg, G. D. (2010). Loss of murine TDP-43 disrupts
motor function and plays an essential role in embryogenesis. Acta Neuropathol.
119, 409-419.
Larroquette, F., Seto, L., Gaub, P. L., Kamal, B., Wallis, D., Larivier̀e, R., Vallée,
J., Robitaille, R. and Tsuda, H. (2015). Vapb /Amyotrophic lateral sclerosis 8
knock-in mice display slowly progressive motor behavior defects accompanying
ER stress and autophagic response. Hum. Mol. Genet. 24, 6515-6529.
Le, N. T. T., Chang, L., Kovlyagina, I., Georgiou, P., Safren, N., Braunstein, K. E.,
Kvarta, M. D., Van Dyke, A. M., Legates, T. A., Philips, T. et al. (2016). Motor
neuron disease, TDP-43 pathology, andmemory deficits in mice expressingALS–
FTD-linked UBQLN2 mutations. Proc. Natl Acad. Sci. USA 113, E7580-E7589.
Li, H.-F. and Wu, Z.-Y. (2016). Genotype-phenotype correlations of amyotrophic
lateral sclerosis. Translational Neurodegeneration 5, 3.
Lino, M. M., Schneider, C. and Caroni, P. (2002). Accumulation of SOD1 mutants
in postnatal motoneurons does not cause motoneuron pathology or motoneuron
disease. J. Neurosci. 22, 4825-4832.
Liu, E. Y., Cali, C. P. and Lee, E. B. (2017). RNA metabolism in neurodegenerative
disease. Dis. Model. Mech. 10, 509-518.
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